Abstract
Patients of Tuberculosis have poor treatment outcome with high mortality. Immunodeficiency appears to be an important risk factor in the development of multi drug resistance (MDR) and extensively drug resistance (XDR) tuberculosis. Mesenchymal stromal cell (MSCs) having immunomodulatory effect, have been used as adjunct autologous treatment. Thereby, it helps in transforming chronic inflammation into productive immune response. Stem cells therapy is based on the principle, that it migrates to the site of injury and forms tissue specific cell type that can replace the damaged tissue. Autologous MSCs have been used as an adjunct treatment in MDR TB in the lungs for accelerating clearance of pathogenic bacteria and early recovery. It appears to be a promising procedure for enhancing the efficacy of anti-TB therapy in MDR and XDR subjects.
Keywords: Multi-drug resistance, extremely drug resistance, tuberculosis, mesenchymal stem cell therapy.
Current Respiratory Medicine Reviews
Title:Stem Cells in MDR-TB and XDR - TB
Volume: 10 Issue: 4
Author(s): Vijay K. Arora, Paramjit S. Dhot and P. Singhal
Affiliation:
Keywords: Multi-drug resistance, extremely drug resistance, tuberculosis, mesenchymal stem cell therapy.
Abstract: Patients of Tuberculosis have poor treatment outcome with high mortality. Immunodeficiency appears to be an important risk factor in the development of multi drug resistance (MDR) and extensively drug resistance (XDR) tuberculosis. Mesenchymal stromal cell (MSCs) having immunomodulatory effect, have been used as adjunct autologous treatment. Thereby, it helps in transforming chronic inflammation into productive immune response. Stem cells therapy is based on the principle, that it migrates to the site of injury and forms tissue specific cell type that can replace the damaged tissue. Autologous MSCs have been used as an adjunct treatment in MDR TB in the lungs for accelerating clearance of pathogenic bacteria and early recovery. It appears to be a promising procedure for enhancing the efficacy of anti-TB therapy in MDR and XDR subjects.
Export Options
About this article
Cite this article as:
K. Arora Vijay, S. Dhot Paramjit and Singhal P., Stem Cells in MDR-TB and XDR - TB, Current Respiratory Medicine Reviews 2014; 10 (4) . https://dx.doi.org/10.2174/1573398X11666150109223613
DOI https://dx.doi.org/10.2174/1573398X11666150109223613 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phenothiazine: A Better Scaffold against Tuberculosis
Mini-Reviews in Medicinal Chemistry Cellular and Molecular Mechanisms of Tumor-Induced T-Cell Tolerance
Current Cancer Drug Targets Targeting Monoamine Oxidases with Multipotent Ligands: An Emerging Strategy in the Search of New Drugs Against Neurodegenerative Diseases
Current Medicinal Chemistry Genetics and Vaccines in the Era of Personalized Medicine
Current Genomics The 4-Quinolone-3-Carboxylic Acid Motif as a Multivalent Scaffold in Medicinal Chemistry
Current Medicinal Chemistry Patent Selections:
Recent Patents on Anti-Infective Drug Discovery Novel Approaches to Control Biofilm Infections
Current Medicinal Chemistry The Adult Patient with Eisenmenger Syndrome: A Medical Update after Dana Point Part III: Specific Management and Surgical Aspects
Current Cardiology Reviews The Role of Autophagy in Rheumatic Disease
Current Drug Targets Mycobacterial tuberculosis Enzyme Targets and their Inhibitors
Current Topics in Medicinal Chemistry The Clinical Relevance of Differential Cell Counts in Induced Sputum and its Relationship with Various forms of Asthma
Current Respiratory Medicine Reviews The Past, Present and Future Subclassification of Patients with Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Editorial (Thematic Issue: Pulmonary Delivery of Systemic Drugs- from Aerosol Generation to Efficacious Delivery)
Current Pharmaceutical Design Hybrid Imidazole-Pyridine Derivatives: An Approach to Novel Anticancer DNA Intercalators
Current Medicinal Chemistry Patent Selection
Recent Patents on Biotechnology T-Lymphocytes: A Target for Stimulatory and Inhibitory Effects of Zinc Ions
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in Methodologies for the Discovery of Antimycobacterial Drugs
Current Bioactive Compounds Pharmacological Activity of Natural Non-glycosylated Triterpenes
Mini-Reviews in Organic Chemistry Salicylanilide Ester Prodrugs as Potential Antimicrobial Agents - a Review
Current Pharmaceutical Design Administration of Exogenous Surfactant and Cytosolic Phospholipase A2α Inhibitors may Help COVID-19 Infected Patients with Chronic Diseases
Coronaviruses